A lthough the replacement of bare-metal stents with drugeluting stents has led to a significant reduction in the rate of angiogenic in-stent restenosis (ISR), ISR occurs in 3% to 20% of patients with a drug-eluting stent, depending on lesion characteristics and patient risk factors, such as diabetes mellitus. [1] [2] [3] Moreover, owing to concerns about a high risk of bleeding in relation to the requirement for prolonged dual antiplatelet therapy after drug-eluting stent placement, bare-metal stents are sometimes used in patients with histories of recurrent gastrointestinal bleeding.
A lthough the replacement of bare-metal stents with drugeluting stents has led to a significant reduction in the rate of angiogenic in-stent restenosis (ISR), ISR occurs in 3% to 20% of patients with a drug-eluting stent, depending on lesion characteristics and patient risk factors, such as diabetes mellitus. [1] [2] [3] Moreover, owing to concerns about a high risk of bleeding in relation to the requirement for prolonged dual antiplatelet therapy after drug-eluting stent placement, bare-metal stents are sometimes used in patients with histories of recurrent gastrointestinal bleeding. 4 ISR, therefore, remains a stent failure that needs to be overcome. Deciphering the mechanisms of ISR will aid in the development of precise treatment strategies.
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Neointimal hyperplasia is the pathogenic hallmark of ISR, involving abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) and extracellular matrix accumulation, and this process eventually results in lumen loss. 5 Inflammation and infiltration of inflammatory cells in response to vascular injury activate vascular wall cells, which secrete proinflammatory mediators and growth factors, triggering proliferation and migration of VSMCs. 6 Such pathological features are mediated and aggravated by oxidative stress. 7 In our previous study, we established diabetic and nondiabetic minipig models of coronary artery ISR after rapamycin-eluting stent implantation. 8, 9 At 6 months after model establishment, animals were euthanized, ISR and non-ISR segments were isolated from diabetic minipigs for explant tissue culture, and secretory proteins in the conditioned media were analyzed. Liquid chromatography tandem mass spectrometry analysis showed that a large number of proteins were significantly increased (≥1.5-fold increase in levels) in conditioned media from ISR segments as compared with levels from non-ISR tissues. Among them, levels of high-mobility group box (HMGB) 2, a member of the HMGB family, were increased ≈2-fold (unpublished data).
The HMGB family consists of HMGB1−4, which are widely distributed in eukaryotic cells. HMGBs regulate DNA transcription, replication, and repair. 10 This family modulates innate immunity and affects various inflammatory diseases. 10, 11 Among the 4 members, HMGB1 plays a role in the pathophysiology of cardiovascular diseases, such as atherosclerosis and intimal hyperplasia, in response to arterial injury. [12] [13] [14] [15] HMGB1 and HMGB2 share high amino acid sequence similarity (>80%), and both are substantially expressed in immune cells. 15, 16 Sequestration of HMGB1 and HMGB2 in cells or blocking their release inhibits immune reactions, implying that HMGB2 plays a role in triggering the immune response. 17, 18 Moreover, HMGB2 is related to the development of inflammatory bowel disease. 19 Increased expression of HMGB2 is associated with poor outcome in patients with hepatocellular carcinoma. 20 However, information regarding the role of HMGB2 in cardiovascular diseases is limited.
In the present study, we investigated whether HMGB2 contributes to ISR in patients and neointimal hyperplasia in mice after vascular injury. We verified our previous proteomic data from minipig experiments, showing that HMGB2 level was significantly increased in stented segments with ISR than in those with no ISR from both diabetic and nondiabetic minipigs. In a clinical study, serum levels of HMGB2 were analyzed in consecutive patients with and without ISR, as determined by follow-up angiography ≈1 year after rapamycin-eluting stent implantation. The proliferation and migration induced by HMGB2 was evaluated in human aortic smooth muscle cells (hASMCs) or mouse-derived VSMCs. Femoral artery wire injuries were made, and neointimal formation was assessed in C57Bl/6 and Hmgb2 -/-mice or mice receiving perivascular administration of HMGB2 or PBS. To decipher the mechanism of HMGB2-induced neointimal hyperplasia, nicotinamide adenine dinucleotide phosphate (NADPH) subunit expression and reactive oxygen species (ROS) generation were evaluated in wire-injured arteries and HMGB2-treated VSMCs. NADPH oxidase inhibitors apocynin or diphenylene iodonium (DPI) were used in mice along with HMGB2 administration and in hASMCs or mouse-derived VSMCs to determine HMGB2-induced effects.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Serum HMGB2 Level Is Associated With the Presence and Severity of ISR in Patients
The baseline characteristics and biomeasurements of ISR and non-ISR group patients are detailed in Table 1 . Patients with ISR had higher rates of smoking, diabetes mellitus, dyslipidemia, and impaired renal function, with more multivessel disease and more severe lesions in coronary arteries, as compared with patients with no ISR. The percent diameter of restenosis was significantly higher in the ISR group than in the group without ISR (72.92±17.80% versus 19.99±13.18%; P<0.001). Notably, serum levels of HMGB2 and hsCRP were significantly increased in the ISR group compared with levels in the non-ISR group (P<0.001). After categorization of the patients according to the presence or absence of diabetes mellitus or ISR, the serum levels of HMGB2 were significantly higher in ISR patients than the levels in non-ISR patients in both diabetic (8.73±6.37 versus 5.35±4.90 μg/L; P<0.001) and nondiabetic participants (6.15±3.59 versus 4.00±3.05 μg/L; P<0.001), with a significant difference between diabetic patients with ISR and nondiabetic subjects with ISR (P<0.001; Figure IIA in the online-only Data Supplement). We further divided the patients based on the tertile distribution of HMGB2. The incidence of ISR was significantly increased across the tertiles of HMGB2 values. The percent diameter restenosis was also significantly correlated with serum levels of HMGB2, with a Spearman's r of 0.479 (P for trend <0.001) after adjustments for potential confounders ( Figure IIB and IIC in the online-only Data Supplement).
Multivariable logistic regression models without (model 1) and with (model 2) HMGB2 are shown in Table 2 . In model 1, among all the potential confounders, diabetes mellitus, dyslipidemia, smoking, history of myocardial infarction, total-to-HDL cholesterol ratio, glomerular filtration rate, high-sensitivity C-reactive protein, left ventricular ejection fraction, use of statins, lesion severity, and stent diameter were independent determinants of ISR. When HMGB2 was further included in model 2 in addition to the other factors in model 1, it remained to be an independent determinant of ISR, with an odds ratio of 6.532 (95% confidence interval, 3.605−11.834; P<0.001) and 2.175 (95% confidence interval, 1.207−3.919; P=0.010) for tertile 3 and 2, respectively, compared with tertile 1. The calibration of model 1 (0.834) and model 2 (0.919) was good. The addition of HMGB2 resulted in a significant improvement of goodness-of-fit and predictive performance with an increase of Nagelkerke R 2 of 7.6% (P<0.001) and C statistic of 0.030 (95% confidence interval, 0.013−0.047; P=0.001) and a net reclassification improvement and integrated discrimination improvement of 8.1% (P=0.011) and 7.0% (P<0.001), respectively. We first verified the results of our previous proteomic analysis and determined HMGB2 expression in stented segments by Western blot analysis. HMGB2 levels were significantly higher in ISR tissue than in non-ISR tissue from both diabetic and nondiabetic minipigs ( Figure 1A and 1B). Then, we determined the levels of HMGB2 in serum and in vascular tissue of C57Bl/6 mice with wire injury-induced neointimal hyperplasia. Serum HMGB2 levels exhibited a 1-fold increase at 3 days and more than a 3-fold increase at ≈7 to 14 days after injury as compared with that in sham mice, with the peak value appearing at ≈1 week ( Figure 1C ). Immunofluorescence analysis revealed that HMGB2 expression was substantially upregulated in the neointima from 0 to 28 days after vascular injury ( Figure 1D and 1E). Consistently, increased HMGB2 levels were observed in injured vascular tissue by Western blot analysis ( Figure 1F ). CD68 macrophages with HMGB2 expression were also recruited to the lesion areas at 7 days ( Figure IVA through IVC in the onlineonly Data Supplement). In cell experiments, lipopolysaccharide stimulation increased the HMGB2 level in culture media of both hASMCs and macrophages in a time-and dose-dependent manner, as detected by Western blot and ELISA assays ( Figure VA through VD in the online-only Data Supplement). These results indicated that activating VSMCs and macrophages promoted the production and release of HMGB2 in response to vascular injury and inflammation. Data are mean±SD or number (%). ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; GFR, glomerular filtration rate; HbA1c, glycosylated hemoglobin A1c; HDL, highdensity lipoprotein; HMGB, high-mobility group box; hsCRP, high-sensitivity C reactive protein; ISR, in-stent restenosis; LDL, low-density lipoprotein; and PCI, percutaneous coronary intervention.
(Continued ) To evaluate the impact of HMGB2 on postinjury neointimal formation, we performed femoral artery wire injury in C57Bl/6 and Hmgb2 -/-mice. Notably, Hmgb2 -/-mice exhibited a remarkable reduction in neointimal growth (28.13±2.40%) and intima-to-media ratio (0.78±0.074) after 4 weeks, as compared with wild-type C57Bl/6 mice (46.56±2.45% and 1.52±0.13), respectively (P<0.05 for both; Figure 2A through 2C). In immunofluorescent analysis, smooth muscle cell layer proliferation, as represented by α-smooth muscle actin staining area in C57Bl/6 mice, was significantly mitigated in Hmgb2 -/-mice ( Figure 2D ). In line with histological findings, wire injury induced a profuse expression of collagen type 1-alpha 1 (Col1a1), collagen type 3-alpha 1 (Col3a1), matrix metalloproteinase-2 (MMP-2), and MMP-9 in vascular tissue of C57Bl/6 mice, the elements responsible for VSMC migration, proliferation, matrix breakdown, and vascular remodeling. The expression of these proteins was, however, significantly decreased in Hmgb2 -/-mice after vascular injury ( Next, we administered PF-127 gel containing mouse recombinant HMGB2 protein or PBS around the ). ACEI indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CTO, chronic total occlusion; DES, drug-eluting stent; GFR, glomerular filtration rate; HbA1c, glycosylated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HMGB, high-mobility group box; hsCRP, highsensitivity C reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and TC, total cholesterol. injured arteries in C57Bl/6 mice. The local administration of HMGB2 markedly increased neointimal growth (63.69±3.22%) and intima-to-media ratio (2.15±0.19) after 4 weeks, as compared with growth on PBS administration (46.67±3.25% and 1.46±0.12, respectively; P<0.05; Figure 2G through 2I). The α-smooth muscle actin-positive staining area also significantly increased in HMGB2-treated mice ( Figure 2J ). Masson's trichrome staining consistently showed that Hmgb2 deletion decreased collagen deposition in injured arteries compared with levels of deposition observed in C57Bl/6 mice. The perivascular administration of HMGB2, in contrast, promoted collagen accumulation when compared with accumulation on PBS administration ( Figure 2K and 2L). All these results indicated that HMGB2 aggravated neointimal hyperplasia in response to vascular injury. High-mobility group box (HMGB) 2 level was upregulated in stented segments of minipigs with in-stent restenosis (ISR) and in vascular tissue of mice after injury. A, HMGB2 protein levels were determined in ISR and non-ISR tissues from both diabetic and nondiabetic minipigs using Western blotting. Briefly, 15 minipigs with diabetes mellitus was induced by intravenous administration of streptozotocin (diabetic group). Another 26 minipigs were placed in the nondiabetic group. Coronary angiography and stent implantation were performed in both groups 2 weeks later. Aspirin (300 mg/d) and Ticlopidine (250 mg/d) were given from 2 days before catheterization to the end of the experiment. After anesthesia, 2 sirolimus-eluting stents were implanted for each animal. Repeat angiography was performed after 6 months. ISR was defined as 50% luminal diameter narrowing. After completion of the experiments, the pigs were euthanized, and the stented vessel segments with or without ISR were harvested for Western blot analysis to determine HMGB2 levels. B, Quantification of A. *P<0.05 vs nonrestenosis of nondiabetic minipigs, n=3; #P<0.05 vs nonrestenosis of diabetic minipigs; n=3. C, Serum HMGB2 levels were determined in mice with femoral artery wire injury at different time points. *P<0.05 vs 0 day; n=6. D, The mouse arteries were harvested at different time points (0, 3, 14, and 28 days), and the isotype control was from a mouse artery harvested 28 days after injury. Representative immunofluorescent images of HMGB2 (red) and α-SMA (green) staining in injured arteries. E. Quantification of HMGB2 changes over time in D. *P<0.05 vs 0 day; n=5. F, HMGB2 protein levels were determined in injured femoral arteries and sham arteries. Representative Western blot (upper) and quantification of protein expression (lower). *P<0.05 vs. sham; n=4. Scale bar: 50 μm.
HMGB2 Induces Neointimal Hyperplasia in Response to Vascular Injury by Promoting VSMC Proliferation and Migration
To assess whether HMGB2 influences the growth and migration of VSMCs in vivo and in vitro, we performed histological examination in injured arteries. VSMC layer proliferation, as reflected by α-smooth muscle actin-positive and proliferating cell nuclear antigen (PCNA)-positive staining cells, was significantly decreased in Hmgb2 -/-mice as compared with proliferation in C57Bl/6 mice ( Figure VIIA and VIIB in the online-only 
HMGB2 Promotes Neointimal Hyperplasia and VSMC Proliferation and Migration via ROS Mediation
ROS activation plays an essential role in vascular inflammation and remodeling in response to injury. 22, 23 To investigate whether HMGB2 induces ROS production and whether ROS mediates the effects of HMGB2, we first examined ROS levels in hASMCs on HMGB2 stimulation. HMGB2 greatly induced ROS production in hASMCs, which was reduced by the addition of NADPH oxidase inhibitor DPI ( Figure 3A and 3B) . HMGB2 significantly increased the number of PCNA-positive staining in hASMCs ( Figure 3C and 3D) and boosted proliferation (by CCK8 [cell counting kit 8] incorporation assay) and migration (by Boyden chamber assay and wound-healing assay) in hASMCs ( Figure  3E through 3I) . However, these effects were significantly inhibited by treatment with an anti-HMGB2 antibody, DPI, or apocynin, but not by adding an IgG control ( Figure 3C through 3I) . Western blot analysis supported the above-presented results, showing that HMGB2-induced increases in cyclinD1, Col1a1, Col3a1, MMP2, and MMP9 expression were abolished by DPI or apocynin (Figure XA through XC in the online-only Data Supplement). We then examined the impact of ROS suppression on HMGB2-induced pathways in hASMCs. Treatment with DPI or apocynin significantly inhibited the HMGB2-induced activation of ERK1/2, p38MAPK, and AKT pathways ( Figure XD and XE in the online-only Data Supplement). Next, we determined ROS level in injured arteries by dihydroethidium staining analysis. Neointimal ROS levels were significantly enhanced 1 month after injury as compared with ROS levels in sham control arteries ( Figure 4A and 4B) . Such ROS enhancement, however, was significantly diminished in neointima of Hmgb2 -/-mice ( Figure 4A and 4B) . Consistently, apocynin administration remarkably suppressed ROS levels and neointimal hyperplasia in mice with perivascular HMGB2 administration ( Figure 4C through 4G) , revealing a crucial role for ROS in mediating the effects of HMGB2 in vivo and in vitro.
HMGB2 Enhances ROS via Increasing the p47phox Phosphorylation in hASMCs
ROS intensity depends on the levels of NADPH oxidase subunits. Previous studies have shown that NADPH oxidase-1 (NOX1) and NOX4 upregulation contributes to ROS-mediated neointimal hyperplasia in response to injury. [24] [25] [26] [27] [28] We, thus, analyzed the levels of NADPH oxidase subunits in injured and control arteries of C57Bl/6 and Hmgb2 -/-mice by Western blotting and immunofluorescence analyses. Notably, the levels of phosphorylated p47phox and NOX1 were significantly increased in injured arteries than in those from sham mice, whereas the protein and mRNA levels of NOX4 were not statistically different between groups (Figure 5A through 5D ; Figure XIA through XIE in the online-only Data Supplement). Interestingly, such injury-induced phosphorylation of p47phox was remarkably lower in Hmgb2 -/-mice than in C57Bl/6 mice, but NOX1 was not altered. This decrease in p47phox phosphorylation was associated with attenuated neointimal formation in Hmgb2 -/-mice after injury ( Figure 5A through 5D ). In agreement with these in vivo data, stimulating hASMCs with HMGB2 significantly increased p47phox phosphorylation after 60 minutes ( Figure 5E ; Figure XIF in the online-only Data Supplement). We next tested whether HMGB2-induced phosphorylation of p47phox contributed to ROS generation, proliferation, and migration in hASMCs by using small interfering RNA (siRNA). We transfected hASMCs with p47phox-siRNA or scramble-siRNA for 24 hours and then stimulated these cells with HMGB2 or PBS. Compared with the phenotype of hASMCs transfected with scramble-siRNA, knockdown of p47phox by siRNA significantly mitigated the HMGB2-induced promotion of ROS generation, growth, and migration in hASMCs ( Figure 5F through 5L) . Western blot analysis showed that knocking down p47phox reduced HMGB2-induced expression of cyclinD1, Col1a1, MMP2, and MMP9 in hASMC ( Figure XIIA through XIIE in the online-only Data Supplement). Moreover, the activation of ERK, p38, and Akt pathways induced by HMGB2 was also attenuated in hASMCs transfected with p47phox-siRNA ( Figure XIIF and XIIG in the online-only Data Supplement). April 2017
Effect of HMGB2 on VSMCs Is Mainly Mediated by Receptor of Advanced Glycation End Products
HMGB1 exerts biological effects through Toll-like receptor (TLR) 2, TLR4, or receptor of advanced glycation end products (RAGE). 15, 29 To ascertain whether these receptors mediated the effect of HMGB2 in VSMCs, we transfected hASMCs with scramble-siRNA, TLR-2-siRNA, TLR-4-siRNA, or RAGE-siRNA for 24 hours and then stimulated these cells with HMGB2 protein, followed by a determination of HMGB2-induced effects. Notably, compared with cells transfected with scramble-siRNA, phosphorylation of p47phox was only reduced in hASMCs transfected with RAGE-siRNA, but not TLR-2-siRNA or TLR-4-siRNA ( Figure 6A ; Figure  XIIIA through XIIIH in the online-only Data Supplement). . E, hASMC proliferation was analyzed using the cell counting kit 8 on treatment with PBS or HMGB2 with the presence or absence of HMGB2 antibody (5 μg/mL), DPI (10 μM), or APO (100 μM). *P<0.05 vs PBS treatment or as indicated; n=4. F, Boyden chamber assay was performed in hASMCs treated by PBS or HMGB2 with the presence or absence of HMGB2 antibody (5 μg/mL), DPI (10 μM), or APO (100 μM). Representative images are shown. G, Migrated cells were quantified by optical density (OD) value of images shown in F. *P<0.05 vs control or as indicated; n=3. H, Wound healing assay was performed in hASMCs treated by PBS or HMGB2 with the presence or absence of HMGB2 antibody (5 μg/mL), DPI (10 μM), or APO (100 μM). Representative images are shown. I, Quantification of wound area is shown in H. *P<0.05 vs control or as indicated; n=6. Cells were preincubated with these agents or buffer alone for 2 h (Ab) or 30 minutes (DPI or APO) at 37°C prior to ROS analysis, the addition to microchemotaxis chambers or proliferation analysis. Scale bar: 50 μm.
Consistently, HMGB2-induced phosphorylation of p47phox was significantly attenuated in Rage VSMCs were greatly suppressed in RAGE-deficient VSMCs ( Figure 6D through 6H) . By confocal microscopy, we observed that neointimal expression of RAGE and HMGB2 was significantly increased after vascular injury and that these 2 proteins were colocalized ( Figure 6I ; Figure XIIIK in the online-only Data Supplement). 
Discussion
In the present study, we showed that (1) serum HMGB2 levels are associated with the presence and severity of ISR in humans; (2) HMGB2 expression is significantly increased in vascular tissue after injury. HMGB2 administration promotes injury-induced neointimal hyperplasia in C57Bl/6 mice, whereas such pathological feature is greatly attenuated in Hmgb2 -/-mice; (3) HMGB2-induced effects in vivo and in vitro are mediated through ROS by augmenting p47phox phosphorylation. Consistently, knockdown of p47phox inhibited HMGB2-induced effects in hASMCs; (4) RAGE, but not TLR4, mediates HMGB2-induced effects in hASMCs. Collectively, our study has demonstrated an association between HMGB2 and ISR in patients and a contributory effect of HMGB2 to injury-induced neointimal hyperplasia in mice.
The HMGB family contains 4 members: HMGB1, HMGB2, HMGB3, and HMGB4. Among them, HMGB1 is closely involved in many cardiovascular diseases, including atherosclerosis and neointimal hyperplasia, after vascular Figure 6 . High-mobility group box (HMGB) 2 promotes p47phox phosphorylation and migration and proliferation of vascular smooth muscle cells (VSMCs) via receptor of advanced glycation end products (RAGE) but not NOX4 (NADPH oxidase-4). A, Human aortic smooth muscle cells (HASMCs) were transfected with scramble-small interfering RNA (siRNA), Toll-like receptor (TLR) 2-siRNA, TLR4-siRNA, or RAGE-siRNA for 24 h, followed by stimulation with PBS or HMGB2. The levels of phospho-p47phox and p47phox were determined by Western blot analysis. Quantification can be found in Figure XIII in the online-only Data Supplement. B and C, VSMCs derived from Rage -/-and Tlr4 -/-mice were treated with PBS or HMGB2. The levels of phospho-p47phox and p47phox were determined by Western blot analysis. Quantification can be found in Figure XIII in the online-only Data Supplement. D, F, and H, VSMCs derived from C57Bl/6 and Rage -/-mice were treated with PBS or HMGB2 in experiments. Reactive oxygen species (ROS), Boyden chamber, and proliferation assay were performed, and respectively, quantified in E and G. *P<0.05 vs C57Bl/6 mouse-derived VSMCs; #P<0.05 vs C57Bl/6 mousederived VSMCs with HMGB2 stimulation; n=3 to 5. I, Immunofluorescence confocal microscopy showed increased expression of HMGB2 and RAGE and colocalization of these 2 proteins in neointima after vascular injury. n=4. Scale bar: 50 μm.
injury.
12-15 HMGB1 and HMGB2 share >80% sequence homology, both containing 2 DNA-binding domains and a long acidic tail. 16 These 2 proteins are profusely distributed in immune cells, 16 indicating their association with the inflammatory response. In the present study, we showed that increased serum HMGB2 levels were associated with ISR in patients undergoing coronary artery interventional treatment. In mice, the local administration of HMGB2 promoted neointimal hyperplasia after vascular injury, while deleting HMGB2 attenuated such pathophysiologic remodeling. These results are supported by in vitro experiments showing that HMGB2 promoted proliferation and migration in hASMCs, with increased expression of cyclin D1, Col1a1, MMP2, and MMP9. Previous studies clearly demonstrated that HMGB1 aggravates injury-induced intimal hyperplasia, and treatment with an anti-HMGB1 antibody or HMGB1 inhibitors suppresses these pathological features. 12, 13, 15, 30, 31 These results, including ours, suggest that HMGB 1 and 2 contribute to intimal hyperplasia.
ROS play a role in the pathophysiological process of many cardiovascular diseases, including atherosclerosis and restenosis after percutaneous coronary intervention. ROS mediate intimal hyperplasia in animal models with vascular injury. 22, 23 In our study, HMGB2 administration enhanced ROS generation in femoral arteries after injury, and stimulating hASMCs with this protein activated ROS, while Hmgb2 deletion significantly decreased ROS levels in injured arteries or VSMCs from Hmgb2 -/-mice. Moreover, inhibiting ROS by treating with NADPH oxidase inhibitors significantly attenuated injury-induced neointimal hyperplasia in mice and HMGB2-induced effects in hASMCs, jointly indicating that ROS are key mediators of neointimal hyperplasia.
Previous studies showed that increases in NOX1 or NOX4 are responsible for ROS production in activated VSMCs or during vascular pathogenic events, including neointimal hyperplasia. [24] [25] [26] [27] [28] P47phox also modulates ROS generation in VSMCs in response to various stimuli, 22, 32, 33 and phosphorylation of p47phox is critical event for NADPH oxidase assembly and activation. 22 Our experiments showed that NOX1 expression is greatly increased in injured arteries; however, its level was not different between C57Bl/6 and Hmgb2 -/-mice, suggesting that NOX1 upregulation is not induced by HMGB2. Interestingly, Hmgb2 deletion significantly decreased the levels of p47phox phosphorylation in femoral arteries after injury and attenuated neointimal hyperplasia. HMGB2 stimulation significantly increased p47phox phosphorylation in hASMCs, while knocking down p47phox using siRNA abolished HMGB2-induced ROS production and other HMGB2 effects. These results indicate that p47phox phosphorylationinduced ROS mediated the effects of HMGB2. However, the detailed mechanism regarding how HMGB2 modulates p47phox phosphorylation needs further clarification.
HMGB1 interacts with RAGE, TLR2, and TLR4 to activate inflammatory cytokine and chemokine production pathways. 15, 29 Of these receptors, the HMGB1-TLR4 pathway has been clearly linked to injury-induced vascular inflammation and intimal hyperplasia. 13 Using siRNA and VSMCs derived from Rage -/-and Tlr4 -/-mice aorta, our study revealed that HMGB2-induced ROS and subsequent effects are mediated through RAGE, a key modulator in neointima formation after vascular injury, 34 but not through TLR2 or TLR4. As observed in confocal analysis, HMGB2 protein was upregulated and colocalized with VSMCs and CD68 + macrophages after vascular injury, suggesting a potential autocrine/paracrine effect of HMGB2 in vascular lesions and macrophages via RAGE. These results represent the different pathways used by HMGB1 and HMGB2 regarding biological and pathogenic effects in VSMCs. However, the reasons and structural domain(s) responsible for this difference remain unclear.
Finally, we recognize that there are limitations in our study. First, our clinical data regarding the HMGB2-ISR association is cross-sectional in nature, thereby allowing us to detect associations but not to formulate risk predictions. Second, there seems to be a disconnection between HMGB2 expression level within the injured vascular tissue and the serum levels and the appearance of ROS after 1 month. In our study, HMGB2 expression and ROS production were time-dependently increased in lesions and were significantly profuse after 1 month of injury, while the serum HMGB2 levels decreased at 28 days after peaking at 7 and 14 days. We do not know whether hyperplasic neointima influences the release of some inflammatory factors into circulation, such as HMGB2. Third, we also showed that HMGB2 expression was upregulated on injury-induced neointimal hyperplasia in mice. Considering that HMGB2 is a RAGE ligand and that HMGB2 expression is increased in ISR tissue from both diabetic and nondiabetic minipigs, we will evaluate the impact of HMGB2 on postinjury vascular neointimal formation in diabetic mice in future studies. Fourth, because both the media (where there are VSMCs) and the adventitia (containing relatively few VSMCs) profusely express HMGB2 after injury, it would be more interesting to assess the contribution of VSMCderived HMGB2 to neointimal hyperplasia by using a VSMCspecific Hmgb2 knockout model. In summary, the present study has demonstrated that increased serum levels of HMGB2 are associated with ISR in patients after percutaneous coronary intervention. HMGB2 promoted neointimal hyperplasia in mice after vascular injury via mediation of p47phox phosphorylationdependent ROS generation (mechanistic diagram presented in Figure XIV in the online-only Data Supplement). Such pathological features are significantly attenuated in Hmgb2 -/-mice.
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